Search
Ergoloid mesylate
go.drugbank.com/drugs/DB01049ApprovedErgoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGlycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigational[A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener. … [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Products: TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADETCladribine
go.drugbank.com/drugs/DB00242ApprovedInvestigationalCladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes. … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell
Categories: P-glycoprotein substratesSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [L24474] It is an agonist of the melanocortin 4 receptor.
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469].
Products: REMİCADE 100 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ (1 ADET), REMICADE 100 MG KONSANTRE IV INFUZYON COZELTISI HAZIRLAMAK ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADETHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. … Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations.
Mixtures: P-TussCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesSulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalSulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. … [L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Synonyms: 3-(p-Aminophenylsulfonamido)-5-methylisoxazoleMixtures: MAXTRIM-P, COTRIMOXAZOL ALMeningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Mixtures: Menomune-A/c/y/w-135, Menomune-A/c/y/w-135Rofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnRofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. … Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers